Friday, June 19, 2026
EULAR 2026 pharmaceutical event banner
← Back to Events
Tier 1 Global Networking: High IMMUNOLOGY CONCLUDED

EULAR 2026 — Not specified, London, UK

The EULAR 2026 Congress will take place at the Excel London from Wednesday, 3 June to Saturday, 6 June 2026. Our organising committee have created a .

Not specified, London, UK June 3 – June 6, 2026
5,000+ Attendees
5 Presentations
3 Companies
2 Drugs
All Events

Presentation data updated Jun 5, 2026, 8:41 AM UTC

Nova Event Impact Score
50 /100
  • Media coverage 10/20
  • Speaker quality 20/20
  • Pipeline relevance 1/20
  • Historical influence 13/20
  • Company participation 6/20

Key Takeaways

Key Themes

immunologyEuropean League Against Rheumatism (EULAR)Pipeline announcementsPartnership deals

Key Companies

AmgenUCBNovartis

Key Drugs

inebilizumabbimekizumab

Key Markets

Europe

Key Opportunities

Partnership dealsLicensing discussionsVendor selection
Best for
Investors & analysts

Amgen at EULAR 2026

2 presentations

ORAL

Phase 3 MITIGATE trial of UPLIZNA® (inebilizumab) in immunoglobulin G4-related disease (IgG4-RD): open-label extension data

Amgen$AMGN inebilizumab(UPLIZNA) Phase Iii immunoglobulin G4-related disease (IgG4-RD)
INVESTOR IMPACT: ★★★★★ 5/5
ORAL Jun 3

New Phase 3 MITIGATE Open-Label Extension Data Support ...

Amgen$AMGN Phase Iii Rare autoimmune and inflammatory diseases
INVESTOR IMPACT: ★★★★☆ 4/5